Business Wire

Study Shows HK L-137 Reduces Inflammation in Healthy Overweight Individuals — Takes Front Line Against Metabolic Syndrome

7.1.2020 15:45:00 EET | Business Wire | Press release

Share

There’s a reason why the health-conscious focus has turned toward foods, supplements and behaviors to reduce inflammation. It’s why House Wellness Foods has put decades of meticulous research into the anti-inflammatory benefits of its unique immunobiotic Lactobacillus plantarum HK L-137, the primary ingredient of its Immuno-LP20®. A just-published study illuminates how this bacillus, in its nonviable form, can be especially important, even lifesaving, to those contending with obesity.

Inflammation is a bodily response we rely on to counter stress, infection and external toxins. But we know that it is also one of the keystones of metabolic dysfunction. Many have gone as far as to suggest that inflammation is the defining characteristic of all infirmity, including the depredating aspects of the aging process itself, leading to eventual organ failure. Unchecked, it can cause the decline of overall health, is linked to a string of metabolic complications, and implicated in dozens of autoimmune diseases from lupus to MS.

Notably, even otherwise healthy individuals under the stress associated with high body mass can suffer a rapidly deteriorating downward spiral; and as we know, obesity is among the most prevalent disease factors in post-industrial society worldwide, (affecting about 40 percent of the U.S. population alone). Simply put, production of inflammatory cytokines increases in individuals carrying more body fat. Though the popular literature avoids the harsh details, the manifestation of this destructive cycle includes insulin resistance, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, hypertension, and dyslipidemia.

The new study from House Wellness Foods laboratories, in cooperation with the Medical Institute of Bioregulation, Kyushu University, describes in detail the process by which inflammation sets its destructive effects in motion. Adipose tissue produces an abundance of inflammatory cytokines, resulting in elevated serum levels of inflammatory mediators (C-reactive protein and leukocyte concentration among them). Tumor necrosis factor and interleukin induce systemic insulin resistance and affect lipid metabolism. There is a concomitant elevation of the serum levels of triglycerides and very-low-density lipoprotein (VLDL).

In the inflammation response, cells communicate via extraordinarily complex means to protect muscles and organs in bodies subjected to ordinary stress or injury. The research paper defines the consequences of lingering inflammation, such as that associated with overweight, and how the inflammatory mediators present in obese or overweight persons need to be suppressed to thwart associated metabolic disorders such as insulin resistance and hyperlipidemia.

Lactic acid-based bacterial probiotics have long shown effectiveness in immune modulation and lipid metabolism. Viable lactobacilli in foods like kefir and other probiotic boosters have proved valuable in lowering total cholesterol levels, but their effect is limited both by their chemistry and the mechanisms by which they act on the body. Multiple peer-reviewed studies have shown that nonviable bacilli, like (heat-killed) HK L-137, are equally, and in many instances more effective in improving obesity-induced inflammation and abnormalities of lipid metabolism, with a more profound impact on immune response as gauged by multiple measurements including enhanced Th1-related immune functions, such as concanavalin A (Con A)-induced proliferation in T cell production.

Heat-killing’s advantage is that it strengthens the bacterial organism’s cellular barriers and fixes its biogenetic material. It stands up to gastric fluids and remains intact through to the ileum of the small intestine, to go on to spur immune response in the mucosa. Heat-killing is what gives HK L-137, the prime constituent of House’s Immuno-LP20, its character as an immunobiotic, and as multiple peer-reviewed studies show, its cell protective and regenerative function supports quality of life improvements that include dramatic reduction of upper respiratory infection and periodontal disease. It also makes HK L-137 available for the widest range of applications due to its ability to withstand processing. Nonviability gives it an unparalleled shelf life without diminishing its effectiveness.

House Wellness Foods has devoted nearly 30 years to both the clinical study of the immunological and protective properties of HK L-137, and the refinement of its natural, food product-based production. The apex of its efforts is Immuno-LP20®, its functional immunobiotic based on HK L-137.

Metabolic syndrome is a crisis of global proportion. Countering it, House Wellness Foods, in its supplements and functional food products, has concentrated its focus on supporting the body’s innate ability to bolster immunity and restore vitality at the cellular level. It is a quest for nothing less than the sustenance of superior health and vigor, and the extension of all life on the planet.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kotaro Soga
House Wellness Foods Corp.
s-hirayama@housefoods.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel Aligner Unveils Six Innovations for 202711.11.2026 18:23:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bindu Saran, VP of Product Strategy, added: “Angel was founded by orthodontic profe

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 16:58:00 EET | Press release

Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gathering of Future Health – A Global Initiative by Abu Dhabi, curated and convened by the Department of Health – Abu Dhabi (DoH) together with Founding Partners PureHealth, M42, Institute for Healthier Living Abu Dhabi (IHLAD) and Mubadala Bio. Held from 20–22 October, the Summit attracted more than 17,300 visitors from 85 countries. It brought together health leaders, researchers, policymakers, investors and inn

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 16:58:00 EET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 15:30:00 EET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 15:22:00 EET | Press release

Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an outcome. End customers for Epinal’s SEB include breathalyzer manufacturers, healthcare, mobile computers & clinical smartphones, handheld bio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye